BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

851 related articles for article (PubMed ID: 32074418)

  • 1. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomised, double-blind, placebo-controlled, phase II/III clinical study in patients aged ≥13 years.
    Yokozeki H; Murota H; Matsumura T; Komazaki H;
    Br J Dermatol; 2024 Apr; ():. PubMed ID: 38629497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
    Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
    Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
    EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
    Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
    JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
    Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
    Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
    JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
    Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H
    Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
    Ruzicka T; Hanifin JM; Furue M; Pulka G; Mlynarczyk I; Wollenberg A; Galus R; Etoh T; Mihara R; Yoshida H; Stewart J; Kabashima K;
    N Engl J Med; 2017 Mar; 376(9):826-835. PubMed ID: 28249150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical evaluation of nemolizumab for prurigo nodularis.
    Brooks SG; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
    Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N
    Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
    Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
    Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
    Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
    J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
    Igarashi A; Katsunuma T; Matsumura T; Komazaki H;
    Br J Dermatol; 2023 Dec; 190(1):20-28. PubMed ID: 37522351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
    Tsoi LC; Hacini-Rachinel F; Fogel P; Rousseau F; Xing X; Patrick MT; Billi AC; Berthier CC; Kahlenberg JM; Lazzari A; Wiegmann H; Ständer S; Piketty C; Julia V; Krishnaswamy JK; Gudjonsson JE
    J Allergy Clin Immunol; 2022 Apr; 149(4):1329-1339. PubMed ID: 34857395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
    Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
    J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
    Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
    Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of dupilumab in prurigo nodularis in elderly patient.
    Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
    Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.